Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Dt Medtech, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Dt Medtech, LLC

Regulatory records
1
Linked recall entries
1
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Dt Medtech, LLC. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 31, 2026 to Jul 31, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NTG appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P160036, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 110 W. Rd., Suite 227, Towson, MD, 21204. Recorded on P160036/S008, decision dated Jul 31, 2026.

Changes described in PMA records

P160036/S008: Hintermann Series H3 Total Ankle Replacement System

FDA’s recorded scope: The second post-approval study (PAS002, Hintermann Series H3 TAR Performance Study) is designed to evaluate the trend in performance between each implant size and assess the outcomes of the primary surgeon of the study (accounting for approximately 80% of the registry) compared to other surgeons that are less familiar with the device. You agree to use a prospective, multicenter, single arm study design, and hypothesis testing to evaluate the performance of the different implant sizes of the Hintermann Series H3 TAR System compared to the Hintermann Series H3 TAR System performance in the PSE cohort. Multiple investigators unfamiliar with the device will be recruited so that one surgeon does not conduct the majority of the cases and to evaluate the impact of experience on overall outcomes. You have agreed to enroll 232 new study subjects at up to 10 US sites and to follow these subjects for 5 years. Study subjects will undergo clinical and radiographic evaluation postoperatively at 6 weeks, 6 months, and yearly afterwards. You have agreed to take reasonable measures to avoid loss to follow-up. A follow-up rate of 85% is expected at each timepoint. You have agreed to collect and analyze information about safety, including any reoperation, revisions or removals of the Hintermann Ankle device, and effectiveness endpoints, including the American Orthopaedic Foot and Ankle Society at 2 years or more, the survivorship (absence of removal/revisions to include polyethylene revision) within 5 years, the percentage of subjects with a serious device-related adverse event other than a revision or removal within 2 years, as well as VAS score, patient satisfaction, and SF-36 for general well-being. You will also collect information about all adverse events reported for these patients, including details of the nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome. Additionally, you have agreed to provide radiographic assessments of all enrolled subjects as well as a detailed explant analysis of any explanted devices during the PAS.

Jul 31, 2026 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Dt Medtech, LLCClass IIJun 17, 2026FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Dt Medtech, LLCPMA supplementJul 31, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.